Eliem Therapeutics Analyst Ratings
Eliem Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Eliem Therapeutics (ELYM) rating was a downgraded with a price target of $0.00 to $0.00. The current price Eliem Therapeutics (ELYM) is trading at is $3.34, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/10/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/28/2022 | 79.64% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 08/16/2022 | 19.76% | SVB Leerink | $9 → $4 | Maintains | Outperform |
| 07/11/2022 | 169.46% | SVB Leerink | $13 → $9 | Maintains | Outperform |
| 04/26/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 04/26/2022 | 289.22% | SVB Leerink | $33 → $13 | Maintains | Outperform |
| 09/07/2021 | 858.08% | Guggenheim | → $32 | Initiates Coverage On | → Buy |
| 09/07/2021 | 947.9% | Stifel | → $35 | Initiates Coverage On | → Buy |
| 09/07/2021 | 888.02% | SVB Leerink | → $33 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行空间 | 分析师公司 | 价格目标变更 | 评级变化 | 之前/现今评级 |
|---|---|---|---|---|---|
| 02/10/2023 | — | HC Wainwright & Co. | 降级 | 买入→中立 | |
| 10/28/2022 | 79.64% | HC Wainwright & Co. | → $6 | 开始覆盖 | 买入 |
| 08/16/2022 | 19.76% | SVB Leerink | 9美元 → 4美元 | 维持不变 | 强于市场表现 |
| 07/11/2022 | 169.46% | SVB Leerink | $13 → $9 | 维持不变 | 强于市场表现 |
| 04/26/2022 | — | 古根海姆 | 降级 | 买入→中立 | |
| 04/26/2022 | 289.22% | SVB Leerink | 33美元 → 13美元 | 维持不变 | 强于市场表现 |
| 09/07/2021 | 858.08% | 古根海姆 | → $32 | 开始覆盖 | 买入 |
| 09/07/2021 | 947.9% | Stifel | →35美元 | 开始覆盖 | 买入 |
| 09/07/2021 | 888.02% | SVB Leerink | → 33美元 | 开始覆盖 | →买入 |
What is the target price for Eliem Therapeutics (ELYM)?
Eliem Therapeutics (ELYM)的目标价是多少？
The latest price target for Eliem Therapeutics (NASDAQ: ELYM) was reported by HC Wainwright & Co. on February 10, 2023. The analyst firm set a price target for $0.00 expecting ELYM to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
Eliem Therapeutics (纳斯达克：ELYM)的最新价格目标由HC Wainwright & Co.于2023年2月10日报告。分析公司设定了0.00美元的目标价，预计ELYm在12个月内下跌（可能下跌100.00%）。在过去一年中有6家分析公司发布了评级。
What is the most recent analyst rating for Eliem Therapeutics (ELYM)?
Eliem Therapeutics（ELYM）最新的分析师评级是什么？
The latest analyst rating for Eliem Therapeutics (NASDAQ: ELYM) was provided by HC Wainwright & Co., and Eliem Therapeutics downgraded their neutral rating.
Eliem Therapeutics（NASDAQ: ELYM）最新的分析师评级由HC Wainwright & Co提供，Eliem Therapeutics下调了他们的中立评级。
When is the next analyst rating going to be posted or updated for Eliem Therapeutics (ELYM)?
Eliem Therapeutics（ELYM）的下一个分析师评级将何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eliem Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eliem Therapeutics was filed on February 10, 2023 so you should expect the next rating to be made available sometime around February 10, 2024.
分析师在进行大量研究后得出股票评级，这包括查阅公开的财务报表、与Eliem Therapeutics的高管和客户交谈，以及收听业绩会议电话。大多数分析师每季度进行一次评级，因此您每年应该获得每家公司每家公司的4个评级。Eliem Therapeutics的最后一个评级是在2023年2月10日提交的，因此您应该在2024年2月10日前后获得下一个评级。
Is the Analyst Rating Eliem Therapeutics (ELYM) correct?
Eliem Therapeutics（ELYM）的分析师评级是否正确？
While ratings are subjective and will change, the latest Eliem Therapeutics (ELYM) rating was a downgraded with a price target of $0.00 to $0.00. The current price Eliem Therapeutics (ELYM) is trading at is $3.34, which is out of the analyst's predicted range.
虽然评级是主观的且会有变化，但最新的Eliem Therapeutics（ELYM）评级是降级，目标价从$0.00下调至$0.00。Eliem Therapeutics（ELYM）目前的交易价格为$3.34，超出了分析师预测的区间。
译文内容由第三方软件翻译。
